Abstract: Metabolic health and positive symptom severity has been investigated in schizophrenia, but not in clinical high risk (CHR) patients. We hypothesized that greater body mass index (BMI) in CHR patients would be related to less positive symptoms. We examined this relationship in CHR patients being treated with 1) no psychotropic medications (n = 58), 2) an antipsychotic (n = 14), or 3) an antidepressant without an antipsychotic (n = 10). We found no relationship between BMI and positive symptoms in unmedicated CHR patients, the majority of whom had a narrow BMI range between 20 and 30. However, in the smaller sample of CHR patients taking an antidepressant or antipsychotic, BMI was negatively correlated with positive symptoms. Although potentially underpowered, these preliminary findings provide initial steps in elucidating the relationships between metabolic health, neurochemistry, and symptom severity in CHR patients.
I
t has been argued that weight gain and insulin resistance (IR) may be beneficial for treating psychosis (Sharma et al., 2014) . For instance, antipsychotic medications induce weight gain and exacerbate IR (Clark, 2004; McIntyre et al., 2001; Tschoner et al., 2007) . Importantly, higher fasting serum levels of insulin are related to less psychotic symptoms in patients with schizophrenia (SCZ) (Chen et al., 2013; Fan et al., 2006) . In healthy persons, acute (9-day) administration of olanzapine or aripiprazole can significantly increase IR in the absence of weight gain (Teff et al., 2013) . Brain imaging studies in healthy humans suggests that obesity and IR may be associated with reduced striatal dopaminergic functioning (Caravaggio et al., 2015a) . Thus, it has been hypothesized that in SCZ, states of hyperinsulinemia may promote a reduction in central dopamine (DA) levels and in turn a reduction in positive symptoms (Caravaggio et al., 2015b) .
Although several studies have examined the relationship between metabolic health and positive symptoms in persons with SCZ, to our knowledge, this has not yet been examined in patients at clinical high risk (CHR) for psychosis. In this preliminary analysis, we investigated whether body mass index (BMI)-a gross, indirect measure of metabolic health and IR-is related to the severity of positive symptoms in CHR individuals. We hypothesized that greater BMI in CHR patients would be related to less positive symptom severity, as measured by the Structured Interview for Psychosis-Risk Syndromes (SIPS) (Miller et al., 2003) . We examined this relationship in CHR patients being treated with 1) no psychotropic medications, 2) an antipsychotic, and 3) an antidepressant without an antipsychotic. This was done because both antidepressants and antipsychotics have been found to alter body weight (Fava, 2000; Himmerich et al., 2015) and both are used in the treatment of psychosis in CHR. Although there are several limitations to the current investigation, we hope this preliminary investigation will prompt future prospective research examining how IR might be related to symptom severity and neurochemistry in persons with attenuated psychotic symptoms.
METHODS

Participants
Participants and clinical assessments were derived from a longitudinal cohort study of CHR patients at the Center of Prevention and Evaluation (COPE) at the New York State Psychiatric Institute/ Columbia University Medical Center. COPE offers treatment to English-speaking individuals, aged 14 to 30 years, who are deemed to be at high risk for psychosis. These CHR individuals were helpseeking and met criteria for at least one of three psychosis-risk syndromes, as assessed with the SIPS.
Statistical Analyses
Statistical analyses were conducted using IBM SPSS Statistics (v.20; IBM Corp, Armonk, NY) and GraphPad (v.6.0; GraphPad Software, La Jolla, CA). The significance level for all tests was set at p < 0.05 (two-tailed). As our study was exploratory and preliminary in nature, we did not explicitly control for multiple comparisons.
RESULTS
Fourteen CHR patients (mean age, 17.75 ± 1.67 years; 2 women) were receiving antipsychotics, 10 were receiving antidepressants (mean age, 20.33 ± 0.97 years; 4 women), and 58 CHR patients were not taking any psychotropic medications (mean age, 22.78 ± 3.34 years) (see Table 1 ). The BMI (mean ± SD) for each group were as follows: unmedicated CHR (26 ± 5.23), antipsychotic treatment (28 ± 5.99), and antidepressant only treatment (27 ± 8.17). BMI did not significantly differ between unmedicated subjects and those receiving and antidepressant 
DISCUSSION
Contrary to our hypotheses, we did not observe a significant correlation between BMI and positive symptom severity in unmedicated CHR subjects. This may be due to several factors, including a reduced BMI range and inherent subject heterogeneity. However, we found that in those CHR patients receiving an antipsychotic or antidepressant, BMI was significantly negatively correlated with positive symptoms. However, these samples were small, and caution must be taken in considering these preliminary findings until replicated with larger samples. Although we did not collect changes in BMI given neuroleptics, these results seem consistent with the "metabolic threshold" hypothesis of neuroleptic treatment. Namely, weight gain/IR induced by neuroleptic medications may be related to improved positive symptoms (Sharma et al., 2014) , perhaps vis-à-vis reduced striatal dopaminergic signaling induced by this metabolic state (Caravaggio et al., 2015a) . However, given that we have only collected BMI, it presently remains unclear whether glucose tolerance/IR abnormalities exist in nonmedicated CHR patients at baseline. This could be addressed by future prospective studies. Of course, as is the case in persons diagnosed with SCZ, it may be that not all CHR patients in our sample have striatal DA abnormalities. The cause of their subthreshold psychotic symptoms may be the result of some other unknown pathology, and thus unrelated to DA or BMI. There are several limitations to the present study. We are limited by the sole use of BMI. We hope our preliminary investigation will prompt research groups to prospectively collect and examine direct markers of metabolic health in CHR patients, in relation to symptom severity and neurochemistry. We did not collect metabolic data before and after treatment with psychotropics. Thus, whether changes in symptoms are related to drug-induced changes in metabolic functioning in CHR subjects is currently unknown and should be investigated by future studies. Future studies should also use larger sample sizes. Notably, we only observed significant negative correlations with BMI, not positive correlations, consistent with our a priori hypotheses.
Although much remains unknown in terms of understanding how metabolic health may relate to psychotic symptoms and neurochemistry in the CHR, our preliminary findings provide rationale and groundwork for addressing these questions.
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